TopicNeuroscience

neuropathic pain

Explore Neuroscience Browse all domains

Content Overview

42Total items

40ePosters

2Seminars

Latest

SeminarNeuroscience

Maladaptive Neuroplasticity in Cortico-limbic Structures: Insights from Surgical Pain Relief in Chronic Neuropathic Facial Pain

Patcharaporn Srisaikaew

University Health Network

Apr 3, 2025

SeminarNeuroscienceRecording

Targeting the Endocannabinoid System for Management of Chemotherapy, HIV and Antiretroviral-Induced Neuropathic Pain

Willias Masocha

Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait

Sep 24, 2020

Chemotherapeutic drugs (used for treating cancer), HIV infection and antiretroviral therapy (ART) can independently cause difficult-to-manage painful neuropathy. Paclitaxel, a chemotherapeutic drug, for example is associated with high incidence of peripheral neuropathy, around 71% of the patients of which 27% of these develop neuropathic pain. Use of cannabis or phytocannabinoids has been reported to improve pain measures in patients with neuropathic pain, including painful HIV-associated sensory neuropathy and cancer pain. Phytocannabinoids and endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), produce their effects via cannabinoid (CB) receptors, which are present both in the periphery and central nervous system. Endocannabinoids are synthesized in an “on demand” fashion and are degraded by various enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). Various studies, including those from our group, suggest that there are changes in gene and protein expression of endocannabinoid molecules during chemotherapy-induced neuropathic pain (CINP), HIV and antiretroviral-induced neuropathic pain. Analysis of endocannabinoid molecule expression in the brain, spinal cord and paw skin using LC-MS/MS show that there is a specific deficiency of the endocannabinoids 2-AG and/or anandamide in the periphery during CINP. Various drugs including endocannabinoids, cannabidiol, inhibitors of FAAH and MGL, CB receptor agonists, desipramine and coadministered indomethacin plus minocycline have been found to either prevent the development and/or attenuate established CINP, HIV and antiretroviral-induced neuropathic pain in a CB receptor-dependent manner. The results available suggest that targeting the endocannabinoid system for prevention and treatment of CINP, HIV-associated neuropathic pain and antiretroviral-induced neuropathic pain is a plausible therapeutic option.

neuropathic pain

Latest

Maladaptive Neuroplasticity in Cortico-limbic Structures: Insights from Surgical Pain Relief in Chronic Neuropathic Facial Pain

Targeting the Endocannabinoid System for Management of Chemotherapy, HIV and Antiretroviral-Induced Neuropathic Pain

OPTOGENETIC INHIBITION OF INFLAMMASOME IN MICROGLIAN TO RELIEVE NEUROPATHIC PAIN

SEX-DEPENDENT EFFECTS OF EARLY LIFE ADVERSITY AND NEUROPATHIC PAIN ON ANXIETY-RELATED BEHAVIOR IN MICE

NEUROPHYSIOLOGICAL EVALUATION OF THE EFFECTS OF REPETITIVE PULSED RADIOFREQUENCY STIMULATION ON A MODEL OF NEUROPATHIC PAIN

REGION-SPECIFIC ALTERATIONS IN A MALE MOUSE MODEL OF NEUROPATHIC PAIN INDUCED-DEPRESSION: TRANSCRIPTOMIC CHARACTERIZATION

CENTRAL AMYGDALA PKCΔ AND TRPA1 MOLECULAR PROFILING IN A RAT MODEL OF CHRONIC NEUROPATHIC PAIN

SEX-DEPENDENT BEHAVIORAL EFFECTS OF CHRONIC MORPHINE IN A MOUSE MODEL OF NEUROPATHIC PAIN

THE SPIDER VENOM PEPTIDE PNTX4(5-5) AS A NEW THERAPEUTIC PROPOSAL FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN

THE ROLE OF CIRCADIAN GENES IN THE THERAPEUTIC EFFECTS OF DULOXETINE AS A TREATMENT FOR NEUROPATHIC PAIN

LIT-002, A HIGHLY POTENT AND SELECTIVE NON-PEPTIDE OXYTOCIN RECEPTOR AGONIST FOR DURABLE RELIEF OF NEUROPATHIC PAIN

NEUROPATHIC PAIN PROMOTES IMPULSIVE CHOICE PREFERENCE THROUGH ORBITOSTRIATAL DYSFUNCTION

SOCIAL EXPOSURE TO CHRONIC NEUROPATHIC PAIN INDUCES SEX-DEPENDENT BEHAVIORAL AND PHYSIOLOGICAL RESPONSES IN RATS

TOPICAL MIROGABALIN AND PREGABALIN ALLEVIATE NEUROPATHIC PAIN VIA PERIPHERAL MECHANISMS BY SUPPRESSING SPINAL NEURONAL HYPERACTIVITY

THE CEREBELLUM CONTRIBUTES TO CONDITIONED PAIN RELIEF PROCESSES IN AN ANIMAL MODEL OF NEUROPATHIC PAIN AND A HUMAN MODEL OF PLACEBO ANALGESIA

SYSTEMATIC TRACING REVEALS ABERRANT RECRUITMENT OF HYPOTHALAMIC CIRCUITRY IN NEUROPATHIC PAIN

SEX-DEPENDENT ANALGESIC EFFECTS OF MIF INHIBITION BY ISO-1 IN A MOUSE MODEL OF NEUROPATHIC PAIN

REPETITIVE TRANSCRANIAL MAGNET STIMULATION AS A NEW TREATMENT CONCEPT FOR NEUROPATHIC PAIN IN SMALL FIBER NEUROPATHY

GAP JUNCTION (CONNEXIN-43) IS A DRUG TARGET FOR RELIEVING NEUROPATHIC PAIN IN RATS

REWIRING PAIN: INVESTIGATING THE ROLE OF THE CENTROLATERAL THALAMUS IN CHRONIC NEUROPATHIC PAIN

TARGETING NK1 AND NLRP3 SIGNALLING PATHWAYS TO ALLEVIATE NEUROPATHIC PAIN IN DIABETIC PERIPHERAL NEUROPATHY

TRPV1-MEDIATED CALCIUM OVERLOAD TRIGGERS MITOCHONDRIAL DYSFUNCTION AND NEURONAL APOPTOSIS IN NEUROPATHIC PAIN

ALTERED SENSORY ENCODING IN THE ACC DRIVES MECHANICAL ALLODYNIA THROUGH PV NEURONS PLASTICITY IN NEUROPATHIC PAIN

Combined electrophysiologic and transcriptomic characterization reveals different functional populations of GABAergic spinal neurons in neuropathic pain mouse model

Differential roles for dysregulated microRNAs after a peripheral nerve injury in neuropathic pain or nerve regeneration

Effect of voluntary wheel running on the anterior cingulate cortex in neuropathic pain mice

Hippocampal function is altered in a model of chronic neuropathic pain

Antiallodynia and antihyperalgesia effects of Cerium oxide nanoparticles in treatment of chronic neuropathic pain in rats

Altered parabrachial nucleus nociceptive processing may underlie central neuropathic pain in Parkinson’s disease

Centrally expressed Cav3.2 T-type calcium channel is critical for the initiation and maintenance of neuropathic pain

Daily record with portable EEG in SCI patients with neuropathic pain

Interneurons in the nucleus accumbens alter their electrophysiological properties in a mouse model of neuropathic pain

mGluR5-mediated deactivation of mPFC via somatostatin-positive interneuron in neuropathic pain mice

Dual PI3Kδ/γ inhibitor Duvelisib prevents development of chemotherapy induced neuropathic pain

Functional alterations of intrinsic networks at various stages of neuropathic pain and comorbidity development

AAV gene therapy delivering recombinant dimeric peptides targeting PICK1 fully relieve chronic neuropathic pain

Glial activation contributes to increased sensitivity of spinal TRPV1 receptors in paclitaxel induced neuropathic pain

Involvement of parvalbumin-positive GABAergic neurons in basal forebrain modulation in a mouse model of neuropathic pain

Modulation of neuropathic pain and tactile perception in spinal cord injury during an exoskeleton training program

Microglial P2X4 in neuropathic pain and associated comorbidities: A gender independent story?

Repetitive prefrontal transcranial direct current stimulation alleviates neuropathic pain via neural remodelling

Role of voltage-dependent potassium currents on trigeminal neuropathic pain